HSP Share Price |
||||
| Open | 89.96 | Change | Price | % |
| High | 89.98 | 1 Day | -0.01 | -0.01 |
| Low | 89.95 | 1 Week | 0.00 | 0.00 |
| Close | 89.95 | 1 Month | 0.00 | 0.00 |
| Volume | 13143972 | 1 Year | 0.00 | 0.00 |
| 52 Week High 17.80 | ||||
| 52 Week Low 8.52 | ||||
| HSP Important Levels | |
| Resistance 2 | 89.98 |
| Resistance 1 | 89.97 |
| Pivot | 89.96 |
| Support 1 | 89.93 |
| Support 2 | 89.92 |
| NYSE USA Most Active Stocks | |||
| RAI | 65.40 | -2.23% | |
| RAI | 65.40 | -2.23% | |
| CPN | 14.92 | 10.52% | |
| CPN | 14.92 | 10.52% | |
| EMC | 29.05 | 0.97% | |
| EMC | 29.05 | 0.97% | |
| EMC | 29.05 | 0.97% | |
| SE | 40.68 | -0.78% | |
| PCS | 11.84 | -0.92% | |
| PCS | 11.84 | -0.92% | |
| NYSE USA Top Gainers Stocks | |||
| NWY | 2.01 | 29.68% | |
| POM | 26.93 | 26.79% | |
| POM | 26.93 | 26.79% | |
| GLF | 0.34 | 25.93% | |
| GLF | 0.34 | 25.93% | |
| THC | 14.45 | 14.23% | |
| THC | 14.45 | 14.23% | |
| THC | 14.45 | 14.23% | |
| FENG | 4.50 | 14.21% | |
| RENN | 8.23 | 12.13% | |
| NYSE USA Top Losers Stocks | |||
| ENL | 15.81 | -66.25% | |
| ENL | 15.81 | -66.25% | |
| ENL | 15.81 | -66.25% | |
| MHR | 0.15 | -42.31% | |
| MHR | 0.15 | -42.31% | |
| MHR | 0.15 | -42.31% | |
| STP | 0.53 | -39.77% | |
| STP | 0.53 | -39.77% | |
| STP | 0.53 | -39.77% | |
| STP | 0.53 | -39.77% | |
Hospira Inc (NYSE: HSP)
| HSP Technical Analysis | 5 |
| As on 2nd Sep 2015 HSP Share Price closed @ 89.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 76.64 & Strong Buy for SHORT-TERM with Stoploss of 89.29 we also expect STOCK to react on Following IMPORTANT LEVELS. | |
| HSP Target for August | |
| 1st Target up-side | N/A |
| 2nd Target up-side | N/A |
| 3rd Target up-side | N/A |
| 1st Target down-side | N/A |
| 2nd Target down-side | N/A |
| 3rd Target down-side | N/A |
Hospira Inc ( NYSE USA Symbol : HSP ) Sector : Healthcare And Other Stocks in Same Sector |
|||||
|
ACG
7.91 -0.01 (-0.13 %) LT : Strong Buy ST : Strong Buy |
ACC
47.25 -0.56 (-1.17 %) LT : Sell ST : Sell |
ABT
48.74 -0.55 (-1.12 %) LT : Strong Buy ST : Buy |
ABT
48.74 -0.55 (-1.12 %) LT : Strong Buy ST : Buy |
AB
23.10 -0.05 (-0.22 %) LT : Buy ST : Strong Sell |
|
|
|
||||||||||||||||||||||
|
Interactive Technical Analysis Chart Hospira Inc ( HSP NYSE USA )
Your Comments and Response on Hospira Inc
HSP Business Profile
Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The companys specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.